Neurovascular protection of alisol A on cerebral ischemia mice through activating the AKT/GSK3β pathway

Huihong Li, Caiyun Zhang, Yangjie Zhou, Yunfei Deng, Xiaoqing Zheng, Xiehua XueAging 2023 · DOI

Abstract: Alisol A, a triterpene isolated from Alisma Orientale, has been shown to exhibit anti-inflammatory effects and vascular protection. This study was designed to observe the effect of alisol A on cerebral ischemia (CI)-induced neurovascular dysfunction in the hippocampus and to further explore the potential mechanisms. The results showed that alisol A treatment improved the neurological deficits and cognitive impairment of CI mice. Alisol A reduced gliosis and improved neuronal/glial metabolism. Accordingly, alisol A inhibited inflammatory factors IL-6 and IL-1β induced by overactivation of astrocytes and microglia, thus protecting the neurovasculature. Furthermore, alisol A promoted the survival of neurons by decreasing the ratio of Bax/Bcl-2, and protected brain microvascular endothelial cells (BMECs) by upregulating the expression of ZO-1, Occludin and CD31. The phosphorylation of protein kinase B (AKT) and glycogen synthase kinase 3β (GSK3β) increased after treatment with alisol A. To explore the underlying mechanism, AKT was inhibited. As expected, the neurovascular protection of alisol A above was eliminated by AKT inhibition. The present study primarily suggested that alisol A could exert neurovascular protection in the hippocampus of CI mice by activating the AKT/GSK3β pathway and may potentially be used for the treatment of CI.

What Problem Does This Paper Address?

Cerebral ischemia (CI) accounts for the vast majority of stroke cases, often leading to severe cognitive impairment and motor dysfunction. While much research focuses solely on saving neurons, modern neuroscience emphasizes the neurovascular unit—the complex interaction between neurons, glial cells (astrocytes and microglia), and blood vessels.

Following a stroke, the hippocampus is particularly vulnerable. The "leakiness" of the blood-brain barrier (BBB), overactivation of inflammatory glial cells (gliosis), and programmed cell death (apoptosis) create a toxic environment that hinders recovery. There is a critical need for treatments that can protect this entire neurovascular ecosystem. The authors hypothesize that Alisol A, known for its anti-inflammatory properties, could be the key.

Chemical structure of Alisol A, a triterpene isolated from Alisma Orientale.

Methods

The study utilized a mouse model of cerebral ischemia induced by temporary bilateral carotid artery occlusion. The researchers divided the mice into four groups: Sham (control), CI (stroke), CI + Alisol A, and CI + Alisol A + an AKT inhibitor.

Key techniques included:

  • Behavioral Testing: Morris Water Maze (MWM) for spatial memory and New Object Recognition Test (NORT) for recognition memory.
  • Magnetic Resonance Spectroscopy (MRS): A non-invasive imaging technique used to measure metabolic markers like N-acetyl aspartate (NAA) for neuronal health and Choline (Cho)/Myo-inositol (MI) for glial activity.
  • Transmission Electron Microscopy (TEM): To visualize the "ultrastructure" of the brain, such as the integrity of tight junctions in blood vessels and the health of mitochondria.
  • Molecular Analysis: Western blotting and immunofluorescence were used to track protein expression related to the BBB (ZO-1, Occludin), inflammation (IL-6, IL-1β), and the AKT/GSK3β survival pathway.

Key Insights and Ideas

  • The Metabolic Balance: Using MRS, the authors showed that Alisol A doesn't just stop cell death; it restores the metabolic balance of the hippocampus. It increased the NAA/Cr ratio (a sign of living neurons) and decreased Cho/Cr and MI/Cr ratios, which are markers of inflammatory gliosis.
  • BBB Fortification: Alisol A was shown to upregulate "tight junction" proteins (ZO-1 and Occludin). TEM images revealed that Alisol A prevented the "swelling" of astrocyte end-feet, effectively "plugging the leaks" in the blood-brain barrier caused by ischemia.
  • The AKT/GSK3β Switch: AKT is a "survival" kinase. When activated (phosphorylated), it inhibits GSK3β, which in turn prevents the cell from triggering its own death (apoptosis) and reduces the production of pro-inflammatory cytokines.
  • Causality via Inhibition: By introducing an AKT inhibitor, the researchers proved that the benefits of Alisol A were not coincidental; when the AKT pathway was blocked, Alisol A’s protective effects vanished.

Key Results

  • Cognitive Recovery: Mice treated with Alisol A showed significantly improved performance in behavioral tests. In the MWM, they spent more time in the target platform and crossed it more frequently. In the NORT, they exhibited a higher discrimination ratio compared to the untreated CI group ($P < 0.001$).
  • Reduced Cell Death: Alisol A decreased the Bax/Bcl-2 ratio, a classic molecular marker for programmed cell death, thereby promoting neuronal survival.
  • Vascular Protection: Expression of CD31 (a marker for blood vessel integrity) and tight junction proteins increased significantly after treatment ($P < 0.05$).
  • Inflammation Suppression: The treatment markedly reduced levels of pro-inflammatory cytokines IL-6 and IL-1β by inhibiting the overactivation of microglia and astrocytes.
Behavioral results showing Alisol A improves spatial and recognition memory, an effect reversed by AKT inhibition.

Limitations and Future Work

While the results are robust in a controlled mouse model, several areas require further exploration:

  • Clinical Translation: Mouse models of stroke involve sudden occlusion, whereas human strokes are often more complex and involve underlying chronic conditions like atherosclerosis or hypertension.
  • Dose-Response: The study used a single dosage (30 mg/kg). Future work is needed to determine the optimal therapeutic window and potential toxicity at higher doses.
  • Long-term Effects: The study focused on a 7-day recovery period; longer-term studies are required to see if the cognitive improvements are permanent.
  • Bioavailability: As a triterpene, the metabolic path of Alisol A from oral ingestion to the brain needs more detailed pharmacokinetic mapping in humans.

Summary updated

Abstract

Alisol A, a triterpene isolated from Alisma Orientale, has been shown to exhibit anti-inflammatory effects and vascular protection. This study was designed to observe the effect of alisol A on cerebral ischemia (CI)-induced neurovascular dysfunction in the hippocampus and to further explore the potential mechanisms. The results showed that alisol A treatment improved the neurological deficits and cognitive impairment of CI mice. Alisol A reduced gliosis and improved neuronal/glial metabolism. Accordingly, alisol A inhibited inflammatory factors IL-6 and IL-1β induced by overactivation of astrocytes and microglia, thus protecting the neurovasculature. Furthermore, alisol A promoted the survival of neurons by decreasing the ratio of Bax/Bcl-2, and protected brain microvascular endothelial cells (BMECs) by upregulating the expression of ZO-1, Occludin and CD31. The phosphorylation of protein kinase B (AKT) and glycogen synthase kinase 3β (GSK3β) increased after treatment with alisol A. To explore the underlying mechanism, AKT was inhibited. As expected, the neurovascular protection of alisol A above was eliminated by AKT inhibition. The present study primarily suggested that alisol A could exert neurovascular protection in the hippocampus of CI mice by activating the AKT/GSK3β pathway and may potentially be used for the treatment of CI.
BibTeX
@inproceedings{li2023neurovascular,
  author = {Huihong Li and Caiyun Zhang and Yangjie Zhou and Yunfei Deng and Xiaoqing Zheng and Xiehua Xue},
  title = {{Neurovascular protection of alisol A on cerebral ischemia mice through activating the AKT/GSK3β pathway}},
  booktitle = {Aging},
  year = {2023},
  doi = {10.18632/aging.205151},
}
Figure